Loading company…
Manifold Biotechnologies designs tissue-targeted biologics, using AI-guided protein design and in vivo screening.
Manifold Biotechnologies, founded in 2019 in Boston, US, develops tissue-targeted biologics through its mDesign platform, which combines high-throughput screening with AI to speed drug development. The company has reported three funding deals, the latest a USD 40.000 mn Series A in May 2022 led by Triatomic Capital, with backing from FPV Ventures, Fifty Years, and Tencent Investment. Gleb Kuznetsov is CEO, and he co-founded the company with Pierce Ogden and Shane Lofgren. The company is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in